Doris Hillemann

7.3k total citations · 1 hit paper
87 papers, 5.0k citations indexed

About

Doris Hillemann is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Doris Hillemann has authored 87 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Epidemiology, 67 papers in Infectious Diseases and 24 papers in Molecular Biology. Recurrent topics in Doris Hillemann's work include Mycobacterium research and diagnosis (68 papers), Tuberculosis Research and Epidemiology (66 papers) and Infectious Diseases and Tuberculosis (11 papers). Doris Hillemann is often cited by papers focused on Mycobacterium research and diagnosis (68 papers), Tuberculosis Research and Epidemiology (66 papers) and Infectious Diseases and Tuberculosis (11 papers). Doris Hillemann collaborates with scholars based in Germany, United Kingdom and Switzerland. Doris Hillemann's co-authors include Sabine Rüsch–Gerdes, Elvira Richter, Catharina Boehme, Stefan Niemann, Wolfgang Wohlleben, Sabine Ruesch-Gerdes, Pamela Nabeta, David Alland, Mark D. Perkins and Martin Jones and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Doris Hillemann

86 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rapid Molecular Detection of Tuberculosis and Rifampin Resistance

2010 1.6k citations Catharina Boehme, Pamela Nabeta et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Doris Hillemann Germany	32	3.9k	3.5k	1.9k	1.0k	315	87	5.0k
Lee W. Riley United States	33	3.0k 0.8×	2.7k 0.8×	1.4k 0.7×	1.1k 1.1×	270 0.9×	65	4.4k
Jeremy W. Dale United Kingdom	32	4.0k 1.0×	3.9k 1.1×	2.0k 1.1×	1.1k 1.1×	586 1.9×	92	5.4k
Jaya Sivaswami Tyagi India	34	2.3k 0.6×	1.8k 0.5×	875 0.5×	1.3k 1.3×	368 1.2×	116	3.5k
Maria Laura Gennaro United States	46	3.4k 0.9×	2.6k 0.7×	888 0.5×	1.9k 1.9×	289 0.9×	123	5.2k
Père-Joan Cardona Spain	41	4.3k 1.1×	3.0k 0.9×	1.2k 0.6×	1.5k 1.5×	221 0.7×	160	6.2k
Martin I. Voskuil United States	37	5.3k 1.4×	4.3k 1.2×	924 0.5×	2.9k 2.9×	1.2k 3.8×	63	7.3k
Vishwa Mohan Katoch India	31	2.1k 0.5×	1.7k 0.5×	737 0.4×	676 0.7×	245 0.8×	94	2.8k
Linda M. Parsons United States	29	3.0k 0.8×	2.7k 0.8×	1.2k 0.6×	905 0.9×	418 1.3×	57	4.6k
Jordi B. Torrelles United States	39	2.6k 0.7×	2.0k 0.6×	415 0.2×	1.3k 1.3×	236 0.7×	122	4.6k
Nadine Honoré France	34	2.4k 0.6×	2.3k 0.6×	697 0.4×	1.3k 1.2×	896 2.8×	55	3.9k

Countries citing papers authored by Doris Hillemann

Since Specialization

Citations

This map shows the geographic impact of Doris Hillemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doris Hillemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doris Hillemann more than expected).

Fields of papers citing papers by Doris Hillemann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doris Hillemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doris Hillemann. The network helps show where Doris Hillemann may publish in the future.

Co-authorship network of co-authors of Doris Hillemann

This figure shows the co-authorship network connecting the top 25 collaborators of Doris Hillemann. A scholar is included among the top collaborators of Doris Hillemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doris Hillemann. Doris Hillemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Svensson, Erik, Sönke Andres, Dorte Bek Folkvardsen, et al.. (2024). Dual-centre evaluation of the FluoroType MTBDR version 2 assay for detection of Mycobacterium tuberculosis complex and resistance-conferring mutations in pulmonary and extrapulmonary samples from Denmark, Germany and Sierra Leone. Clinical Microbiology and Infection. 30(8). 1055–1060.

Kolbe, Katharina, Inke R. König, Regina Scherließ, et al.. (2022). Lipobiotin-capture magnetic bead assay for isolation, enrichment and detection of Mycobacterium tuberculosis from saliva. PLoS ONE. 17(7). e0265554–e0265554. 4 indexed citations

Dreyer, Viola, Sönke Andres, Doris Hillemann, et al.. (2021). Microevolution of Mycobacterium tuberculosis Subpopulations and Heteroresistance in a Patient Receiving 27 Years of Tuberculosis Treatment in Germany. Antimicrobial Agents and Chemotherapy. 65(7). e0252020–e0252020. 5 indexed citations

Diel, Roland, Giovanni Sotgiu, Sönke Andres, Doris Hillemann, & Florian P. Maurer. (2020). Cost of multidrug resistant tuberculosis in Germany—An update. International Journal of Infectious Diseases. 103. 102–109. 10 indexed citations

Peter, Jonny, Fernanda Carvalho de Queiroz Mello, Nguyễn Thị Ngọc Lan, et al.. (2018). Performance of the TB-LAMP diagnostic assay in reference laboratories: Results from a multicentre study. International Journal of Infectious Diseases. 68. 44–49. 20 indexed citations

Heyckendorf, Jan, Sönke Andres, Claudio U. Köser, et al.. (2017). What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy. 62(2). 80 indexed citations

Nikolayevskyy, Vladyslav, Doris Hillemann, Elvira Richter, et al.. (2016). External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study. PLoS ONE. 11(4). e0152926–e0152926. 23 indexed citations

Diel, Roland, Albert Nienhaus, Doris Hillemann, & Elvira Richter. (2015). Cost–benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals. European Respiratory Journal. 47(2). 575–587. 15 indexed citations

Napiórkowska, Agnieszka, Sabine Rüsch–Gerdes, Doris Hillemann, Elvira Richter, & Ewa Augustynowicz–Kopeć. (2014). Characterisation of pyrazinamide-resistant Mycobacterium tuberculosis strains isolated in Poland and Germany. The International Journal of Tuberculosis and Lung Disease. 18(4). 454–460. 8 indexed citations

10.

Hillemann, Doris, Sven Hoffner, Daniela María Cirillo, et al.. (2013). First Evaluation after Implementation of a Quality Control System for the Second Line Drug Susceptibility Testing of Mycobacterium tuberculosis Joint Efforts in Low and High Incidence Countries. PLoS ONE. 8(10). e76765–e76765. 9 indexed citations

11.

Blakemore, Robert, Pamela Nabeta, Amy L. Davidow, et al.. (2011). A Multisite Assessment of the Quantitative Capabilities of the Xpert MTB/RIF Assay. American Journal of Respiratory and Critical Care Medicine. 184(9). 1076–1084. 91 indexed citations

12.

Homolka, Susanne, Christian G. Meyer, Doris Hillemann, et al.. (2010). Unequal distribution of resistance-conferring mutations among Mycobacterium tuberculosis and Mycobacterium africanum strains from Ghana. International Journal of Medical Microbiology. 300(7). 489–495. 23 indexed citations

13.

Boehme, Catharina, Pamela Nabeta, Doris Hillemann, et al.. (2010). Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. New England Journal of Medicine. 363(11). 1005–1015. 1639 indexed citations breakdown →

14.

Richter, Elvira, Sabine Rüsch–Gerdes, & Doris Hillemann. (2009). Drug-susceptibility testing in TB: current status and future prospects. Expert Review of Respiratory Medicine. 3(5). 497–510. 44 indexed citations

15.

Richter, Elvira, Sabine Rüsch–Gerdes, & Doris Hillemann. (2007). First Linezolid-Resistant Clinical Isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 51(4). 1534–1536. 86 indexed citations

16.

Greinert, U, Doris Hillemann, Christoph Lange, & Elvira Richter. (2007). Antibiotikaresistente Tuberkulose. Medizinische Klinik. 102(12). 957–966. 2 indexed citations

17.

Stamme, Cordula, Lutz Thon, Dieter Adam, et al.. (2006). MaxiK Blockade Selectively Inhibits the Lipopolysaccharide-Induced IκB-α/NF-κB Signaling Pathway in Macrophages. The Journal of Immunology. 177(6). 4086–4093. 47 indexed citations

18.

Wohlleben, Wolfgang, et al.. (1992). Identification and characterization of phosphinothricin-tripeptide biosynthetic genes in Streptomyces viridochromogenes. Gene. 115(1-2). 127–132. 31 indexed citations

19.

Hillemann, Doris, Alfred Pühler, & Wolfgang Wohlleben. (1991). Gene disruption and gene replacement inStreptomycesvia single stranded DNA transformation of integration vectors. Nucleic Acids Research. 19(4). 727–731. 83 indexed citations

20.

Wohlleben, Wolfgang, et al.. (1988). Nucleotide sequence of the phosphinothricin N-acetyltransferase gene from Streptomyces viridochromogenes Tü494 and its expression in Nicotiana tabacum. Gene. 70(1). 25–37. 182 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact